Checkpoint inhibitors in older patients with advanced non-small cell lung cancer

Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer management improving overall survival and providing durable responses with a favorable toxicity profile. New questions have emerged regarding the efficacy and safety of immunotherapy among older adults, typically underrepresented in...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2023-08, Vol.188, p.104056-104056, Article 104056
Main Authors: Reale, Maria Lucia, Romano, Gianpiero Diego, Paolelli, Loretta, Leo, Silvana
Format: Article
Language:English
Subjects:
Elderly patients
Geriatric assessment
Immunotherapy
NSCLC
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer management improving overall survival and providing durable responses with a favorable toxicity profile. New questions have emerged regarding the efficacy and safety of immunotherapy among older adults, typically underrepresented in clinical trials. Several factors have to be taken into account in order to reduce the realistic risk of over or under-treatment of this growing subgroup of patients. In this perspective, geriatric assessment and screening tools should be implemented in clinical practice; moreover older patients’ inclusion into adapted-designed clinical trials should be promoted. In this review, we discuss immunotherapy activity in advanced non-small cell lung cancer (NSCLC) older patients, the role of the comprehensive geriatric assessment, treatment toxicity and its management with a focus on future perspectives in this rapidly evolving scenario. [Display omitted] •Immunotherapy has revolutionized management in lung cancer patients of all ages.•Older adults with advanced NSCLC are underrepresented in clinical trials.•Attempts to evaluate immunotherapy among frail older adults are ongoing.•Toxicity management should consider comorbidities in a multidisciplinary approach.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2023.104056